The addition of valsartan to optimized therapy in a cohort of Japanese patients with coronary heart disease and hypertension provides. Description: RETRACTION: The editors of the European Heart Journal have retracted the article reporting data/results of the Jikei Heart Study. The Lancet has formally retracted the Jikei Heart Study paper, originally published in The retraction had been widely anticipated for more.
|Published (Last):||18 May 2004|
|PDF File Size:||9.52 Mb|
|ePub File Size:||18.95 Mb|
|Price:||Free* [*Free Regsitration Required]|
The report identifies concern over the reliability of the blood pressure data: The report also comments on the affiliation of the person entrusted with the statistical analysis, Nobuo Shirahashi. Although we were initially satisfied with their response, in we published a letter from Dr Yui reporting further concerns. Dr Azam also told us: Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: The government is now investigating how to recover monies from Novaritis, a company obtaines so much moneny based on false and fabrictated data.
I hope many more journals will take the same detailed approach. Matsubara is not an author on the Jikei study. We became aware of this development on April 29,and on May 2 we wrote to Jikei University asking for details of the investigation and requesting that we be kept informed. But we soon became aware that there was concern in Japan about the trial.
Lancet retracts Jikei Heart Study of valsartan following investigation – Retraction Watch
There should be some accountability here by executuves at Novartis. If the CNS journals did the right thing, we would have seen several more retractions recently McGill etc.
An investigating committee headed by Professor Hashimoto from Jikei University was established.
He held the position until Taken together, these findings indicate that there is now sufficient doubt as to the integrity of the Jikei Heart Study and the obfuscation over affiliation of the study statistician for The Lancet formally to retract the paper from the scientific record.
Sub-studies will explore the effect in patients with diabetes mellitus, hyperlipidemia and the effects of combination of drugs. Your email address will not be published.
Too heaart skin in the game, as duplications force retraction of psoriasis paper. The Lancet deserves a tip of our hat for such a detailed note. We wrote again on July 31 after we were made aware that a press conference had been held.
In October,we received correspondence expressing concern about the similarity of the standard deviations of the mean blood pressure measurements in the two studies, and we invited the authors to comment. The primary endpoint will be the onset of any cardiovascular event. Concerns about the Jikei Heart Study. Leave a Reply Cancel reply Your email address will not be published. Eur Heart J ; Follow Follow this blog Get every new post delivered right to your inbox.
Given this finding, we now wish to retract the Jikei Heart Study on the grounds that we no longer have confidence in the published results.
When the Jikei Heart Study was first published, Staessen and Richart 2 congratulated the investigators on their report. Another outrageous and potentiall quite dangerous violoation of medical, scientific, and human ethics by Stuudy Pharma trying to sell their products.
Accumulated sales of Diovan in Japan reaches 12 billion dollars US!
Asian patients including Japanese were under-represented in these trials, however, and no large-scale clinical trials of ARBs have yet been performed in Japan. We wrote again on June 4 and June 19 asking when the investigation might be completed. It is therefore important to verify that the results of these studies are also valid for Japanese patients.
The follow-up period will be three years. Of course, The Lancet has been burned before Wakefield… and this is a clinical trial not basic science — hence sanity has prevailed.
Our attempts to obtain a response from Mr Shirahashi were hindered by his recent retirement from Novartis, but the Global Head of Medical Affairs, Dr Usman Azam, did share with The Lancet that Mr Shirahashi had been employed by Novartis throughout the period of the trial and its publication. Sum and substance in the Jikei Heart Study. Sorry, your blog cannot share posts by email.
Several recent clinical trials have demonstrated that angiotensin II receptor blockers ARBs have cardiovascular as well as renal protective effects. Papers on potential cancer drugs retracted for image manipulation. Valsartan in a Japanese population with hypertension and other cardiovascular disease Jikei Heart Study: Secondary endpoints will include death from any cause, changes in left ventricular size and function, renal function, changes in neuro-hormonal levels and quality-of-life assessments.
This site uses Akismet to reduce spam.
Lancet retracts Jikei Heart Study of valsartan following investigation
This is outragenous given all those incomes come from healthinsurance and copay form patients. Larry Husten, at Cardiobrief, has been following the story in detail, and notes that the saga began with questions about papers by Hiroaki Matsubarawho hrart has eight retractions.
Learn how your comment data is processed.